Healthcare Stocks In News (JAZZ, ONXX, ATHX, POZN, IMGN, COV)
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares soared 17.23% to $52.99 after the company late Thursday said that it has reached a definitive agreement with EUSA Pharma Inc. , where Jazz Pharmaceuticals has agreed to acquire EUSA Pharma, a privately-held, specialty pharmaceutical company with headquarters in the United States and United Kingdom, for $650 million in cash(1) and a potential $50 million milestone payable in cash based upon its lead product, Erwinaze(TM) (asparaginase Erwinia chrysanthemi), achieving a specified U.S. net sales target in 2013.
Onyx Pharmaceuticals Inc (NASDAQ:ONXX) declined 1.25% to $46.43. The U.S. Food and Drug Administration will review the Company’s new drug application for carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies.
The Company will release its first quarter 2012 financial results on May 14, 2012.
Athersys Inc (NASDAQ:ATHX) soared 3.70% to $1.40. The Company announced a scheduled meeting with the FDA was held to discuss the results of its recently completed clinical trial involving the administration of MultiStem to patients being treated for leukemia or other conditions that place them at risk of Graft versus Host Disease.
POZEN Inc (NASDAQ:POZN) declined 19.79% to $6.20. C.K. Cooper started coverage on the stock with a buy rating and price target set at $11.00.
ImmunoGen Inc (NASDAQ:IMGN) is up 0.47% to $12.72 after the Company announced third quarter results. Net loss was $18.7 million or $0.24 per share compared to net loss of $15.0 million or $0.22 per share in the same quarter of the last year. Revenues were $3.3 million compared to $5.2 million in the same period last year.
Covidien plc (NYSE:COV) declined 0.40% to $54.82.The Company reported second quarter profit of $497 million or $1.02 per share compared to $455 million or 91 cents per share in the prior year period. Revenue rose 5.2% to $2.95 billion. However, analysts expected earnings per share of $1.03 on revenue of $2.9 billion. Gross margin rose to 57.9% from 57%